HeartCore Enterprises, Inc. (HTCR) Company Overview

What does HeartCore Enterprises do today?

HeartCore Enterprises, Inc. is a Tokyo-headquartered, Delaware-incorporated micro-cap company listed on the Nasdaq Capital Market under HTCR. Its identity changed materially in late 2025. The business that investors are analyzing now is not primarily the customer-experience software vendor that originally came public. HeartCore is repositioning around cross-border financial consulting, especially helping Japanese companies prepare for U.S. public listings, while retaining smaller software-development operations through subsidiaries. The company's own corporate website describes the current direction as financial consulting and digital solutions.

Which activities remain inside the group?

HeartCore's continuing operations in the quarter ended March 31, 2026 included Go IPO and related consulting through HeartCore Financial and its Japan branch, business and management consulting through Higgs Field, customized software work through Sigmaways, and software development through HeartCore Luvina in Vietnam. That perimeter changed again after quarter-end: on June 22, 2026, HeartCore sold its entire 51% interest in Sigmaways and ended its operational involvement, according to the June 2026 Form 8-K. Future reported revenue should therefore become more concentrated in consulting and the remaining Vietnam development operation.

How does HeartCore make money?

The answer has two layers. Operationally, HeartCore earns cash service fees for listing preparation, document conversion, introductions to professional advisers, internal-control support, U.S. GAAP conversion, English-language materials and assistance with S-1 or F-1 filings. The official Go IPO service page positions the company as a coordinator that connects Japanese issuers with the legal, audit and underwriting ecosystem required for a U.S. listing.

Why are cash fees only part of the economics?

The consulting contracts can also provide warrants or stock-acquisition rights. As of March 31, 2026, disclosed cash fees ranged from $380,000 to $900,000 per client, while potential equity rights generally represented 1% to 4% of a client's fully diluted capital, exercisable at nominal prices such as $0.01 or JPY1. Cash consideration is recognized as performance progresses. Noncash consideration is measured under accounting rules and later remeasured when it becomes marketable securities or warrants. This creates a business model in which one successful client can produce a large accounting gain, but market-price declines can later reverse part of that value through fair-value losses.

Which revenue source was largest in Q1 2026?

What did the 2025 strategic reset change?

HeartCore's history matters because the company changed the asset base that originally supported its public listing. The strategic narrative moved from enterprise software and digital transformation toward capital-markets consulting. The decisive transaction was the October 31, 2025 sale of HeartCore Japan for approximately JPY1.8 billion, or about $12 million at the disclosed reference rate. The sale Form 8-K explicitly states that HeartCore intended to concentrate on Go IPO consulting.

1. 2009
   HeartCore Japan was founded as the original software operating company, establishing the enterprise-technology base and customer relationships behind the later U.S. listing.
2. 2021
   HeartCore Enterprises was incorporated in Delaware and completed a share exchange that placed the Japanese operating company under the U.S. holding company.
3. 2022
   The company listed on Nasdaq and launched Go IPO, turning its own cross-border listing experience into a client service.
4. 2023
   HeartCore acquired 51% of Sigmaways and formed HeartCore Financial, broadening both software services and financial consulting.
5. 2025
   HeartCore sold HeartCore Japan, established Higgs Field and classified the divested software business as discontinued operations, creating a one-time gain but removing a recurring revenue base.
6. April 2026
   A 1-for-20 reverse split became effective, and Nasdaq later confirmed restored minimum-bid-price compliance.
7. June 2026
   HeartCore divested Sigmaways for up to $650,000, further narrowing the organization toward consulting and remaining international development operations.

Why does discontinued operations accounting matter?

FY2025 net income of $5.493M looks profitable, but continuing operations lost $4.184M. The difference was chiefly $9.677M of income from discontinued operations, including the gain associated with the HeartCore Japan sale. Students and investors should therefore avoid treating FY2025 consolidated net income as a normalized earnings base. The transaction improved reported equity and generated receivables from the sale, but it also removed approximately $7M to $8M of annual revenue that management said had historically been generated by HeartCore Japan.

What does HeartCore's latest quarter show?

The latest official operating period is the quarter ended March 31, 2026. HeartCore's Q1 2026 Form 10-Q shows a company still carrying meaningful fixed public-company and administrative costs while its revenue base contracts. Revenue fell 40.5% year over year to $1.246M, cost of revenue declined only 24.4%, and gross profit fell 86.4% to $74,045. The result was a 5.9% gross margin, compared with 26.0% in Q1 2025.

Why did the loss narrow while operations weakened?

The common-shareholder net loss improved by $1.187M from Q1 2025, but the improvement came mainly below the operating line. Other expenses fell to $418,745 from $1.840M because the fair-value loss on marketable securities was much smaller. Operating loss actually widened by $350,148 because the lower gross profit more than offset a 6.9% reduction in operating expenses. This distinction is critical: lower investment volatility helped the bottom line, but the underlying service business did not demonstrate operating leverage.

Why are Go IPO economics unusual?

Go IPO is neither a conventional investment bank nor a standard recurring-revenue advisory service. HeartCore states that it does not solicit investors, negotiate securities sales, structure securities transactions or provide legal, accounting or investment advice. Its role is closer to a cross-border project manager: prepare documentation, translate materials, help clients convert accounting data, coordinate outside professionals and support exchange-listing processes. This narrow scope reduces regulated activity, but it also means HeartCore depends on external auditors, lawyers, underwriters and the client's own execution.

What creates the upside?

A client that completes a successful listing can create value beyond the cash fee. In FY2024, one large Go IPO transaction generated approximately $13M of warrant revenue, explaining much of the difference between FY2024 revenue of $22.686M and FY2025 revenue of $8.969M. That history proves the model can create large outcomes, but it also demonstrates concentration: one exceptional engagement can dominate a year's reported revenue and make year-over-year comparisons misleading.

What creates the downside?

The model is also working-capital-light in physical assets but not necessarily low-risk. It requires skilled cross-border coordination, outside support and a public-company cost structure. Q1 2026 consulting revenue was only $25,747 while consulting-related cost of revenue was $157,771, evidence that engagement activity can consume resources before large milestones are recognized. For valuation, the relevant question is how often the 16 signed clients convert into cash fees, completed registrations and monetizable securities, not simply how many agreements have been announced.

How financially strong is HeartCore?

HeartCore had $774,033 of cash and cash equivalents at March 31, 2026, down from $1.986M at December 31, 2025. It also held $3.394M of marketable securities, $273,859 of warrant investments and $1.383M of current proceeds receivable from the HeartCore Japan sale. Total current assets were $6.872M and working capital was $1.011M. These resources provide more support than the cash balance alone suggests, but marketable securities can fluctuate and sale proceeds may be collected on contractual schedules rather than immediately.

What does the annual baseline say?

The FY2025 Form 10-K filing reported $8.969M of revenue, $3.151M of gross profit and $6.273M of operating expenses. Continuing operations lost $4.184M, while discontinued operations generated $9.677M of income, resulting in $5.493M of consolidated net income. Total assets were $13.061M and total shareholders' equity was $7.283M at December 31, 2025. Adjusted EBITDA was reported at $6.5M, but because that non-GAAP figure begins with consolidated net income and removes selected items, it should not replace analysis of continuing operating cash flow.

How should capital allocation be interpreted?

HeartCore paid $3.305M of common dividends during FY2025 and later authorized a share-repurchase program of up to $2.0M, disclosed in the February 2026 announcement. At the same time, Q1 cash fell by $1.212M, and Series A preferred shares carry a 10% cumulative dividend; $27,968 accrued in Q1 2026. Returning capital can signal management confidence, but for a loss-making micro-cap it competes directly with the liquidity needed to fund advisory delivery, public-company costs and possible delays in monetizing client securities.

Who owns HTCR and how is it governed?

HeartCore has one vote per common share, but the ownership base is not fully dispersed. The 2025 definitive proxy statement reported founder, chairman and CEO Sumitaka Yamamoto with 10,658,823 pre-split shares, or 45.7% of outstanding common stock as of July 28, 2025. Directors and executive officers as a group held 57.4%. The company had ceased to qualify as a Nasdaq controlled company because Yamamoto's voting stake had fallen below 50%, but his ownership still represented substantial strategic influence.

What changed after the reverse split?

A 1-for-20 reverse split became effective in April 2026, as described in the official split announcement. The Q1 filing retroactively adjusted per-share data and reported 1,441,565 common shares outstanding as of May 15, 2026. In July 2026, an official Schedule 13G disclosed Hnatko Capital's 7.1% stake. Because the share count is small, conversions, equity financing, warrants and repurchases can all move ownership percentages materially.

What gives HeartCore a competitive position?

HeartCore does not have a conventional software moat after selling its principal Japanese software subsidiary. Its strongest potential advantage is specialized cross-border process knowledge: Japanese-language client acquisition, familiarity with U.S. registration workflows, experience coordinating advisers, and credibility from having completed its own Nasdaq listing. The client pipeline of 16 agreements as of March 31, 2026 indicates demand, and multiple prior clients have reached U.S. public markets. These resources resemble relationship capital and execution know-how more than patented technology or network effects.

Who are the real competitors?

Competition comes from several directions: Japanese securities firms and financial advisers that can guide overseas listings; U.S. investment banks and law firms that offer broader transaction capabilities; accounting and consulting firms that handle U.S. GAAP, internal controls and filing preparation; and boutique cross-border advisers. HeartCore's narrower non-broker role can make it flexible, but clients may prefer an integrated provider with a stronger balance sheet, a larger professional staff or direct underwriting capacity.

How would an MBA framework classify the moat?

What opportunities and risks could change the story?

HeartCore's opportunity is asymmetric: a handful of successful listings could generate large cash fees and valuable equity positions relative to the company's present revenue base. Management also established Higgs Field to support a wider financial-services direction, and the remaining platform may pursue M&A advisory or related cross-border services. A smaller post-divestiture organization could eventually lower costs and focus management attention. The offset is that execution risk is unusually high because results depend on client readiness, regulatory review, capital-market windows and the value of securities received as compensation.

Which risks are most financially material?

• Revenue concentration and timing: one FY2024 warrant transaction contributed about $13M, while no comparable item occurred in FY2025.
• Liquidity: Q1 2026 operating cash use exceeded quarter-end cash, making securities monetization and receivable collection important.
• Cost rigidity: Q1 2026 general and administrative expense was $1.572M, essentially unchanged despite a 40.5% revenue decline.
• Market access: the April 2026 reverse split restored minimum-bid-price compliance, but small-cap listing standards and trading liquidity remain strategic constraints.
• Preferred and equity financing: the Series A carries a 10% cumulative dividend and conversions can dilute common holders.

Which KPIs matter most for a HeartCore DCF?

A conventional DCF built from reported net income would be unreliable because FY2025 included a large disposal gain and because fair-value changes in warrants and marketable securities move through earnings. The model should begin with continuing operations and reconstruct cash economics. Forecast consulting cash fees separately from noncash client securities, then apply explicit probabilities to client milestones. Software revenue should be adjusted for the Sigmaways divestiture rather than extrapolated from Q1 2026.

What should be excluded from normalized cash flow?

The FY2025 gain from discontinued operations should be treated as a nonrecurring transaction, not a terminal-growth input. Fair-value gains and losses on client securities should be scenario-modeled rather than capitalized at a fixed multiple. Likewise, the authorization of a $2.0M repurchase does not itself create value; the relevant variables are actual purchases, funding source, discount to intrinsic value and the opportunity cost of reducing liquidity. A DCF for HeartCore is therefore closer to a venture-style probability model layered onto a small consulting cost base than to a stable perpetuity model.

What is the key takeaway for a DCF analysis?

HeartCore matters as a case study in strategic reinvention. It used a software-company listing to create a Japan-to-U.S. IPO advisory service, sold the original Japanese software subsidiary, divested Sigmaways and retained a pipeline of 16 Go IPO agreements. That creates potentially large upside from a few successful client outcomes, but the latest quarter shows the cost of the transition: revenue contracted, gross margin fell to 5.9%, operating loss widened and cash declined to $0.774M.

The strongest evidence supporting the story is the signed-client pipeline, demonstrated ability to receive both cash and equity compensation, and balance-sheet value from marketable securities and divestiture receivables. The weakest evidence is the absence of stable consulting revenue, the mismatch between quarterly gross profit and administrative cost, continuing negative operating cash flow, internal-control weakness and dilution risk. The company's Q1 2026 earnings release should be read together with later divestiture filings because the operating perimeter changed after March 31.